Nicotine effects on general semantic priming in Parkinson's disease.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide) in the context of parkinson's disease, published as a randomized controlled trial.

In young healthy nonsmokers, effects of nicotine on semantic processing have been observed under strategy-based priming procedures but not under more general priming procedures (Holmes, Chenery, & Copland, 2008; Holmes, Chenery, & Copland, 2010).

Effects of nicotine under general priming procedures, however, may be mediated by baseline priming levels that are below optimum such as when compromised by disease.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

What Was Measured

Effects of nicotine under general priming procedures, however, may be mediated by baseline priming levels that are below optimum such as when compromised by disease.

Topics PubMed links to this paper include Age Factors, Case-Control Studies, Cognition, Nicotine, Nicotinic Agonists, Parkinson Disease and Semantics.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in people with parkinson's disease.

The publication is from 2011 (Experimental and clinical psychopharmacology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, Parkinson's disease research.